Barclays’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.63M | Buy |
+27,400
| New | +$4.69M | ﹤0.01% | 1867 |
|
|
2025
Q3 | – | Sell |
-50,000
| Closed | -$6.33M | – | 5597 |
|
|
2025
Q2 | $6.33M | Buy |
50,000
+29,400
| +143% | +$3.61M | ﹤0.01% | 1915 |
|
|
2025
Q1 | $2.63M | Hold |
20,600
| – | – | ﹤0.01% | 2424 |
|
|
2024
Q4 | $2.72M | Buy |
+20,600
| New | +$2.9M | ﹤0.01% | 2664 |
|
|
2024
Q3 | – | Sell |
-111,825
| Closed | -$15.3M | – | 5368 |
|
|
2024
Q2 | $15.3M | Buy |
111,825
+43,625
| +64% | +$5.82M | ﹤0.01% | 1028 |
|
|
2024
Q1 | $9.36M | Sell |
68,200
-399,700
| -85% | -$54.6M | ﹤0.01% | 1441 |
|
|
2023
Q4 | $63.6M | Buy |
467,900
+377,300
| +416% | +$46M | 0.02% | 567 |
|
|
2023
Q3 | $11.1M | Sell |
90,600
-398,300
| -81% | -$50.7M | 0.01% | 961 |
|
|
2023
Q2 | $62.1M | Buy |
488,900
+393,600
| +413% | +$51.1M | 0.04% | 390 |
|
|
2023
Q1 | $12.3M | Buy |
95,300
+48,800
| +105% | +$6.39M | 0.01% | 1072 |
|
|
2022
Q4 | $6.1M | Buy |
+46,500
| New | +$6.01M | ﹤0.01% | 1483 |
|
|
2020
Q3 | – | Sell |
-5,500
| Closed | -$752K | – | 5360 |
|
|
2020
Q2 | $752K | Sell |
5,500
-64,900
| -92% | -$8.27M | ﹤0.01% | 3005 |
|
|
2020
Q1 | $7.58M | Sell |
70,400
-7,300
| -9% | -$840K | 0.01% | 1167 |
|
|
2019
Q4 | $9.36M | Sell |
77,700
-79,800
| -51% | -$8.9M | 0.01% | 1455 |
|
|
2019
Q3 | $15.7M | Buy |
157,500
+65,400
| +71% | +$6.85M | 0.01% | 1026 |
|
|
2019
Q2 | $10M | Sell |
92,100
-7,800
| -8% | -$830K | 0.01% | 1350 |
|
|
2019
Q1 | $11.2M | Sell |
99,900
-25,700
| -20% | -$2.82M | 0.01% | 1152 |
|
|
2018
Q4 | $12.1M | Buy |
125,600
+60,600
| +93% | +$6.43M | 0.01% | 1039 |
|
|
2018
Q3 | $7.93M | Sell |
65,000
-77,100
| -54% | -$9.08M | 0.01% | 1425 |
|
|
2018
Q2 | $15.6M | Buy |
142,100
+56,100
| +65% | +$6M | 0.01% | 933 |
|
|
2018
Q1 | $9.18M | Sell |
86,000
-102,900
| -54% | -$11.4M | 0.01% | 1219 |
|
|
2017
Q4 | $20.2M | Sell |
188,900
-155,800
| -45% | -$16.7M | 0.02% | 794 |
|
|
2017
Q3 | $38.3M | Sell |
344,700
-82,800
| -19% | -$8.85M | 0.04% | 405 |
|
|
2017
Q2 | $44.2M | Buy |
427,500
+265,500
| +164% | +$26.1M | 0.05% | 312 |
|
|
2017
Q1 | $15.8M | Sell |
162,000
-203,100
| -56% | -$19.4M | 0.02% | 651 |
|
|
2016
Q4 | $32.3M | Buy |
365,100
+140,400
| +62% | +$12.8M | 0.03% | 397 |
|
|
2016
Q3 | $21.7M | Sell |
224,700
-146,400
| -39% | -$13.9M | 0.02% | 518 |
|
|
2016
Q2 | $31.8M | Buy |
371,100
+212,400
| +134% | +$19.1M | 0.04% | 357 |
|
|
2016
Q1 | $13.8M | Sell |
158,700
-220,200
| -58% | -$19.7M | 0.02% | 621 |
|
|
2015
Q4 | $42.7M | Sell |
378,900
-543,900
| -59% | -$59M | 0.05% | 329 |
|
|
2015
Q3 | $93.2M | Buy |
922,800
+279,600
| +43% | +$33.5M | 0.11% | 152 |
|
|
2015
Q2 | $78.9M | Buy |
643,200
+386,400
| +150% | +$46.3M | 0.09% | 189 |
|
|
2015
Q1 | $29.4M | Sell |
256,800
-269,400
| -51% | -$29.7M | 0.03% | 516 |
|
|
2014
Q4 | $53.1M | Buy |
526,200
+286,800
| +120% | +$27.9M | 0.05% | 337 |
|
|
2014
Q3 | $21.8M | Sell |
239,400
-874,800
| -79% | -$76.8M | 0.02% | 679 |
|
|
2014
Q2 | $95.5M | Sell |
1,114,200
-529,800
| -32% | -$41.7M | 0.1% | 160 |
|
|
2014
Q1 | $129M | Buy |
1,644,000
+1,621,200
| +7,111% | +$135M | 0.15% | 114 |
|
|
2013
Q4 | $1.73M | Sell |
22,800
-1,217,100
| -98% | -$86.3M | ﹤0.01% | 2826 |
|
|
2013
Q3 | $86.4M | Buy |
1,239,900
+1,184,100
| +2,122% | +$77.6M | 0.1% | 156 |
|
|
2013
Q2 | $3.23M | Buy |
+55,800
| New | +$3.23M | ﹤0.01% | 2016 |
|
Other funds holding IBB
CB
Barclays's IBB Position: Q1 2026 in Review
Barclays reduced its iShares Biotechnology ETF (IBB) stake by 33% in Q1 2026, selling an estimated $37.8M and leaving 450,734 shares worth $76.1M. The position accounts for 0.02% of the portfolio, ranked #590.
Barclays first reported a position in IBB in Q2 2013 and has held it in 52 quarters since. The position peaked at $376M in Q4 2019. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.
- Barclays held 450,734 shares of iShares Biotechnology ETF worth $76.1M as of Q1 2026.
- Barclays sold 221,207 iShares Biotechnology ETF shares in Q1 2026, an estimated $37.8M.
- iShares Biotechnology ETF made up 0.02% of Barclays's portfolio in Q1 2026, its #590 holding.
- Barclays first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 52 quarters since.
- Barclays's iShares Biotechnology ETF position peaked at $376M in Q4 2019.
- 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.